Lysophosphatidic acid receptor-3 increases tumorigenicity and aggressiveness of rat hepatoma RH7777 cells

Molecular Carcinogenesis

Volumn 52, Issue 4, 2013, Pages 247-254

  Okabe, Kyoko ^a   Hayashi, Mai ^a   Kato, Kohei ^a   Okumura, Mai ^a   Fukui, Rie ^a   Honoki, Kanya ^b   Fukushima, Nobuyuki ^a   Tsujiuchi, Toshifumi ^a  

^a KINKI UNIVERSITY   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cell migration; Liver tumor; Lpar3; Rat; Tumorigenicity

Indexed keywords

CISPLATIN; DOXORUBICIN; GLUTATHIONE TRANSFERASE P1; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN;

AGGRESSIVENESS; ANIMAL CELL; ARTICLE; CARCINOGENICITY; CELL ASSAY; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE; GENE EXPRESSION; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; TUMOR INVASION; ANIMAL; CELL MOTION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; LIVER; LIVER TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

RATTUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CISPLATIN; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; LIVER; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; P-GLYCOPROTEINS; RATS; RECEPTORS, LYSOPHOSPHATIDIC ACID; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 84877285814     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21851     Document Type: Article

References (36)

1. Lin M-E, Herr DR, Chun J. Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 2010; 91: 130-138.
2. Aoki J, Inoue A, Okudaira S. Two pathway for lysophosphatidic acid production. Biochim Biophys Acta 2008; 1781: 513-518.
3. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: Signaling and biology. Annu Rev Biochem 2004; 73: 321-354.
4. An S, Bleu T, Halmark OG, Goetzl EJ. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem 1998; 273: 7906-7910.
5. Bandoh K, Aoki J, Hosono H, et al. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem 1999; 274: 27776-27785.
6. Contos JJA, Ishii I, Chun J. Lysophosphatidic acid receptors. Mol Pharmacol 2000; 58: 1188-1196.
7. Fang X, Gaudette D, Furui T. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann NY Acad Sci 2000; 905: 188-208.
8. Fang X, Schummer M, Mao M, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 2002; 1582: 257-264.
9. Fujita T, Miyamoto S, Onoyama I, Sonoda K, Mekada E, Nakano H. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett 2003; 192: 161-169.
10. Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MAV. Overexpression of Edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res 1999; 5: 4308-4318.
11. Goetzl EJ, Dolezalova H, Kong Y, et al. Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res 1999; 59: 5370-5375.
12. Shida D, Watanabe T, Aoki J, et al. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab Invest 2004; 84: 1352-1362.
13. Schulte KM, Beyer A, Kohrer K, Oberhauser S, Roher HD. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: Over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int J Cancer 2001; 92: 249-256.
14. Tsujino M, Fujii M, Okabe K, Mori T, Fukushima N, Tsujiuchi T. Differential expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in human colon cancer cells. Virchows Arch 2010; 457: 669-676.
15. Okabe K, Hayashi M, Wakabayashi N, et al. Different expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in mouse tumor cells. Pathobiology 2010; 77: 309-314.
16. Yamada T, Furukawa M, Hotta M, et al. Mutations of lysophosphatidic acid receptor-1 gene during progression of lung tumors in rats. Biochem Biophys Res Commun 2009; 378: 424-427.
17. Obo Y, Yamada T, Furukawa M, et al. Frequent mutations of lysophosphatidic acid receptor-1 gene in rat liver tumors. Mutat Res 2009; 660: 47-50.
18. Wakabayashi N, Tsujino M, Tajiri M, et al. No mutations of lysophosphatidic acid receptor genes in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine in rats. J Toxicol Pathol 2010; 3: 63-66.
19. Yu S, Murph MM, Lu Y, et al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008; 100: 1630-1642.
20. Hayashi M, Okabe K, Yamawaki Y, et al. Loss of lysophosphatidic acid receptor-3 enhances cell migration in rat lung tumor cells. Biochem Biophys Res Commun 2011; 405: 450-454.
21. Hooks SB, Santos WL, Im D-S, Heise CE, Macdonald TL, Lynch KR. Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent. J Biol Chem 2001; 276: 4611-4621.
22. Okabe K, Hayashi M, Yamawaki Y, et al. Possible involvement of lysophosphatidic acid receptor-5 gene in the acquisition of growth advantage of rat tumor cells. Mol Carcinog 2011; 50: 635-642.
23. Shano S, Hatanaka K, Ninose S, Moriyama R, Tsujiuchi T, Fukushima N. A Lysophosphatidic acid receptor lacking the PDZ-binding domain is constitutively active and stimulates cell proliferation. Biochim Biophys Acta 2008; 1783: 748-759.
24. Okabe K, Hayashi M, Yoshida I, Nishimura K, Fukushima N, Tsujiuchi T. Distinct DNA methylation patterns of lysophosphatidic acid receptor genes during rat hepatocarcinogenesis induced by a choline deficient L-amino acid defined diet. Arch Toxicol 2011; 85: 1303-1310.
25. Shida D, Kitayama J, Yanaguchi H, et al. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1cells through LPA1. Cancer Res 2003; 63: 1706-1711.
26. Nakajima IA, Sasaguri S, Nagase H, Mori Y. Coculture of human breast adenocarcinoma MCF-7cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and3 in fibroblasts. Cancer Res 1995; 71: 1039-1045.
27. Sautin YY, Crawford JM, Svetlov SI. Enhancement of survival by LPA via Erk1/Erk2 and PI 3-kinase/Akt pathway in a murine hepatocyte cell line. Am J Physiol 2001; 281: C2010-C2019.
28. Okabe K, Kato K, Teranishi M, et al. Induction of lysophosphatidic acid receptor-3 by 12-O-tetradecanoylphorbol-13-acetate stimulates cell migration of rat liver cells. Cancer Lett 2011; 309: 236-242.
29. McCawley LJ, Matrisian LM. Matrix metalloproteinases: Multifunctional contributors to tumor progression. Mol Med Today 2000; 6: 149-156.
30. Svetlov SI, Sautin YY, Crawford JM. EDG receptors and hepatic pathophysiology of LPA and S1P: EDG-ology of liver injury. Biochim Biophys Acta 2002; 1582: 251-256.
31. Park SY, Jeong KJ, Panupinthu N, et al. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene 2011; 30: 1351-1359.
32. Shida D, Kitayama J, Yamaguchi H, et al. Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells. Exp Cell Res 2004; 301: 168-178.
33. Tsujiuchi T, Shimizu K, Onishi M, et al. Aberrant expressions of lysophosphatidic acid receptor genes in lung and liver tumors of rats. J Toxicol Pathol 2006; 19: 137-141.
34. Zaslavsky A, Singh LS, Tan H, Ding H, Liang Z, Xu Y. Homo- and hetero-demerization of LPA/SIP receptors, OGR1 and GPR4. Biochim Biophys Acta 2006; 1761: 1200-1212.
35. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-234.
36. Sau A, Tregno FP, Valentino F, Federici G, Caccuri AM. Glutathine transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys 2010; 500: 116-122.